高级检索
当前位置: 首页 > 详情页

A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma

文献详情

编号/登记号:
注册时间:
研究开始时间:
研究结束时间:
项目类型:
多中心研究:
参与国家:
招募状态:
试验分期:
研究疾病/适应症:
研究类型:
研究负责人:
研究单位: [1]BeiGene [2]St. Joseph Heritage Healthcare,Fullerton,California,United States,92835 [3]University of Southern California Norris Comprehensive Cancer Center,Los Angeles,California,United States,90089-0112 [4]Northwestern Medicine Cancer Center Warrenville,Warrenville,Illinois,United States,60555 [5]Henry Ford Hospital,Detroit,Michigan,United States,48202 [6]Toledo Clinic Cancer Center,Toledo,Ohio,United States,43623 [7]San Antonio Military Medical Center,Fort Sam Houston,Texas,United States,78234 [8]Millennium Oncology,Houston,Texas,United States,77090 [9]Imelda Ziekenhuis,Antwerp,Belgium,2600 [10]UZ Antwerpen,Antwerp,Belgium,2650 [11]Cliniques universitaires Saint-Luc,Brussels,Belgium,1000 [12]University Hospitals Leuven,Leuven,Belgium,3000 [13]Centre Hospitalier Universitaire (CHU) de Liege - Site du Sart Tilman,Liege,Belgium,4000 [14]Anhui Medical University - The Second Hospital,Hefei,Anhui,China,230601 [15]Beijing Friendship Hospital,Beijing,Beijing,China,100050 [16]Beijing Cancer Hospital,Beijing,Beijing,China,100142 [17]Peking Union Medical College Hospital,Beijing,Beijing,China,100730 [18]Fujian Medical University Union Hospital,Fuzhou,Fujian,China,350001 [19]The First Affiliated Hospital of Fujian Medical University,Fuzhou,Fujian,China,350005 [20]Fujian Provincial Cancer Hospital,Fuzhou,Fujian,China,350014 [21]The First Affiliated Hospital of Xiamen University,Xiamen,Fujian,China,361004 [22]The First Hospital, Sun Yat-sen University,Guangzhou,Guangdong,China,510080 [23]The Sixth Affiliated Hospital of Sun Yat-sen University,Guangzhou,Guangdong,China,510655 [24]Cancer Hospital of Shantou University Medical College,Shantou,Guangdong,China,515031 [25]Peking University Shenzhen Hospital,Shenzhen,Guangdong,China,518035 [26]Affiliated Hospital of Hebei University,Baoding,Hebei,China,71000 [27]Fourth Hospital of Hebei Medical University,Shijiazhuang,Hebei,China,050011 [28]Harbin Medical University Cancer Hospital,Harbin,Heilongjiang,China,150081 [29]The First Affiliated Hospital of Xinxiang Medical University,Xinxiang,Henan,China,453100 [30]Henan Cancer Hospital,Zhengzhou,Henan,China,450008 [31]The First Affiliated Hospital of Zhengzhou University,Zhengzhou,Henan,China,450052 [32]Hubei Cancer Hospital,Wuhan,Hubei,China,400037 [33]Xiangyang Central Hospital,Xiangyang,Hubei,China,441000 [34]Hunan Cancer Hospital,Changsha,Hunan,China,410013 [35]The First People's Hospital Of Changzhou,Changzhou,Jiangsu,China,213003 [36]Huai'an Second People's Hospital,Huai'an,Jiangsu,China,223002 [37]Jiangsu Province Hospital,Nanjing,Jiangsu,China,210029 [38]Nanjing Drum Tower Hospital,Nanjing,Jiangsu,China,21008 [39]Nantong Tumor Hospital,Nantong,Jiangsu,China,226000 [40]The Affiliated Hospital of Xuzhou Medical University,Xuzhou,Jiangsu,China,221002 [41]Jiangxi Cancer Hospital,Nanchang,Jiangxi,China,330029 [42]The First Hospital of Jinlin University,Changchun,Jilin,China,130021 [43]Shandong Cancer Hospital,Jinan,Shandong,China,250117 [44]Shandong Linyi Tumor Hospital,Linyi,Shandong,China,371300 [45]WeiFang People's Hospital,Weifang,Shandong,China,261000 [46]Fudan Cancer Hospital,Shanghai,Shanghai,China,200032 [47]Shanxi Provincial People's Hospital,Taiyuan,Shanxi,China,140100 [48]The Second Affiliated Hospital of Xi'an Jiaotong University(Xibei Hospital),Xi'an,Shanxi,China,710014 [49]Sichuan Academy of Medical Sciences& Sichuan Provincial People's Hospital,Chengdu,Sichuan,China,610071 [50]Yunnan Cancer Hospital - Oncology,Kunming,Yunnan,China,650100 [51]Hangzhou First People's Hospital,Hangzhou,Zhejiang,China,310006 [52]The First Affiliated Hospital, Zhejiang University,Hangzhou,Zhejiang,China,310006 [53]Zhejiang Cancer Hospital,Hangzhou,Zhejiang,China,310022 [54]CHRU Besançon,Besançon,France,25000 [55]CHRU de Brest Hôpital Morvan,Brest,France,29200 [56]Centre Georges-Francois Leclerc,Dijon,France,21079 [57]Center Oscar Lambret - Alliance Member,Lille,France,59000 [58]Hopital Prive Jean Mermoz,Lyon,France,69008

关键词: Unresectable metastatic second-line squamous esophagus chemotherapy paclitaxel docetaxel irinotecan

研究目的:
The purpose of this study was to evaluate the efficacy and safety of tislelizumab as second line treatment in participants with advanced unresectable/metastatic ESCC that had progressed during or after first line therapy.

资源点击量:15266 今日访问量:3 总访问量:979 更新日期:2025-05-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 河北大学附属医院 技术支持:重庆聚合科技有限公司 地址:保定市莲池区裕华东路212号